Get the Stockscreener App
21.53
14.36%
-3.61
Arcus Biosciences Inc stock is traded at $21.53, with a volume of 7.42M.
It is down -14.36% in the last 24 hours and up +7.65% over the past month.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
See More
Previous Close:
$25.14
Open:
$21.15
24h Volume:
7.42M
Relative Volume:
4.59
Market Cap:
$2.66B
Revenue:
$247.00M
Net Income/Loss:
$-249.00M
P/E Ratio:
-6.9676
EPS:
-3.09
Net Cash Flow:
$-267.00M
1W Performance:
-15.40%
1M Performance:
+7.65%
6M Performance:
+130.27%
1Y Performance:
+25.47%
1-Day Range:
$20.35
$24.00
1-Week Range:
$20.35
$26.40
52-Week Range:
$6.50
$26.40
Arcus Biosciences Inc Stock (RCUS) Company Profile
Name
Arcus Biosciences Inc
Sector
Industry
Phone
(510) 694-6200
Address
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
21.53 | 3.11B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-21-24 | Initiated | H.C. Wainwright | Neutral |
| Oct-08-24 | Initiated | Wells Fargo | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Nov-23-20 | Initiated | Evercore ISI | Outperform |
| Apr-03-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Sep-27-19 | Initiated | Mizuho | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Oct-09-18 | Initiated | Wedbush | Outperform |
| Apr-09-18 | Initiated | Citigroup | Buy |
| Apr-09-18 | Initiated | Goldman | Neutral |
| Apr-09-18 | Initiated | Leerink Partners | Outperform |
View All
Arcus Biosciences Inc Stock (RCUS) Latest News
Arcus Biosciences (NYSE:RCUS) Shares Gap DownHere's What Happened - MarketBeat
Arcus Biosciences (NYSE:RCUS) Price Target Raised to $32.00 at HC Wainwright - MarketBeat
Arcus Biosciences Target of Unusually Large Options Trading (NYSE:RCUS) - MarketBeat
HC Wainwright & Co. Maintains Arcus Biosciences (RCUS) Buy Recommendation - Nasdaq
Arcus Calls Quits On Anti-TIGIT Candidate After Phase III Termination - Citeline News & Insights
Arcus shifts effort, bears down on would-be ‘anchor’ in RCC - BioWorld MedTech
Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug - Benzinga
H.C. Wainwright raises Arcus Biosciences stock price target to $32 on lower expenses - Investing.com Canada
Why Arcus Biosciences just reversed its 287% eight-month winning streak - MSN
Why Did Arcus Biosciences Stock Slump 10% Today? - Asianet Newsable
Truist Securities lowers Arcus Biosciences stock price target on trial failure - Investing.com
RCUS: HC Wainwright & Co. Raises Price Target for Arcus Bioscien - GuruFocus
Truist Securities Adjusts Arcus Biosciences Price Target to $30 From $39, Maintains Buy Rating - marketscreener.com
Arcus Biosciences (RCUS) Shares Decline Over 11% in Recent Tradi - GuruFocus
Arcus scraps late-stage cancer trial after weak survival data - Reuters
Arcus Biosciences (RCUS) Drops After Halting Phase 3 Cancer Tria - GuruFocus
Arcus Biosciences Stock (RCUS) Collapses 17% after Failed Stomach Cancer Study - TipRanks
GILD: Gilead and Arcus End STAR-221 Study Due to Lack of Efficac - GuruFocus
Arcus, Gilead to Discontinue Phase 3 Trial of Potential Cancer Treatment -- Update - marketscreener.com
Arcus Biosciences Discontinuing Gastric, Esophogeal Cancer Candidate Trial; Shares Fall - marketscreener.com
Gilead and Arcus halt late-stage study for anti-TIGIT cancer drug - Seeking Alpha
Arcus Biosciences to Discontinue Phase 3 Trial of Potential Cancer Treatment - marketscreener.com
Arcus Biosciences stock falls after discontinuing phase 3 cancer study By Investing.com - Investing.com Australia
Arcus Biosciences Discontinues Phase 3 STAR-221 Study - TradingView — Track All Markets
Arcus Provides Update On Phase 3 STAR-221 Study And Concentrates Its Research And Development Investment On Casdatifan And Emerging Inflammation And Immunology Portfolio - TradingView — Track All Markets
Gilead, Arcus scrap late-stage trial of cancer drug combo - Yahoo
Arcus Biosciences (NYSE: RCUS) ends STAR-221, backs casdatifan and I&I pipeline into 2028 - Stock Titan
Arcus cancels work on Gilead-partnered cancer combo after trial setback - Yahoo Finance
Decliners Report: Why Arcus Biosciences Inc stock attracts global investors2025 Volatility Report & Weekly Watchlist for Consistent Profits - moha.gov.vn
Avoiding Lag: Real-Time Signals in (RCUS) Movement - news.stocktradersdaily.com
Arcus Biosciences Announces New Employment Inducement Grants - marketscreener.com
Arcus Biosciences (NYSE: RCUS) sets $25.80 inducement grant under 2020 plan - Stock Titan
Arcus Biosciences (NYSE:RCUS) Reaches New 1-Year HighWhat's Next? - MarketBeat
Is Arcus Biosciences Stock Built to Withstand a Pullback? - Trefis
Fisher Asset Management LLC Decreases Stock Holdings in Arcus Biosciences, Inc. $RCUS - MarketBeat
Insider Selling: Arcus Biosciences (NYSE:RCUS) President Sells 82,997 Shares of Stock - MarketBeat
Arcus Biosciences, Inc. $RCUS Shares Acquired by Tema Etfs LLC - MarketBeat
Arcus Biosciences (NYSE:RCUS) Downgraded by Wall Street Zen to Sell - MarketBeat
Is Arcus Biosciences Inc. stock cheap by valuation metricsWeekly Market Outlook & Low Risk High Win Rate Stock Picks - Newser
Can Arcus Biosciences Inc. stock ride next bull market cycleShort Setup & Real-Time Market Trend Scan - Newser
Decheng Capital LLC Has $1.30 Million Holdings in Arcus Biosciences, Inc. $RCUS - MarketBeat
How Arcus Biosciences Inc. stock performs during market turbulenceJuly 2025 Review & Weekly High Potential Alerts - Newser
What is the fair value estimate for Arcus Biosciences Inc. stock in 2025Earnings Overview Report & Safe Entry Momentum Stock Tips - Newser
How Arcus Biosciences Inc. stock behaves in tightening cyclesJuly 2025 Levels & Weekly High Conviction Ideas - Newser
RCUS: Casdatifan shows superior efficacy in RCC, with pivotal trials and strong financial backing - TradingView
Arcus Biosciences (NYSE:RCUS) Hits New 52-Week HighStill a Buy? - MarketBeat
Arcus Biosciences, Inc. $RCUS Shares Purchased by Geode Capital Management LLC - MarketBeat
How Arcus Biosciences Inc. stock compares with market leadersJuly 2025 Analyst Calls & Safe Entry Point Alerts - Newser
Arcus Biosciences (NYSE:RCUS) CAO Alexander Azoy Sells 1,900 Shares - MarketBeat
Arcus Biosciences stock hits 52-week high at 26.32 USD By Investing.com - Investing.com Australia
Arcus Biosciences stock hits 52-week high at 26.32 USD - Investing.com
Arcus Biosciences Inc Stock (RCUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):